CN101129400B - 玉竹多糖在制备治疗冠心病药物中的应用 - Google Patents
玉竹多糖在制备治疗冠心病药物中的应用 Download PDFInfo
- Publication number
- CN101129400B CN101129400B CN2006101113430A CN200610111343A CN101129400B CN 101129400 B CN101129400 B CN 101129400B CN 2006101113430 A CN2006101113430 A CN 2006101113430A CN 200610111343 A CN200610111343 A CN 200610111343A CN 101129400 B CN101129400 B CN 101129400B
- Authority
- CN
- China
- Prior art keywords
- solomonseal rhizome
- fragrant solomonseal
- rhizome polyoses
- group
- compare
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000756042 Polygonatum Species 0.000 title claims abstract description 51
- 235000008737 Polygonatum biflorum Nutrition 0.000 title claims abstract description 50
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 208000029078 coronary artery disease Diseases 0.000 title claims description 18
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 24
- 102000004190 Enzymes Human genes 0.000 claims abstract description 7
- 108090000790 Enzymes Proteins 0.000 claims abstract description 7
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 14
- 210000004165 myocardium Anatomy 0.000 claims description 13
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000002107 myocardial effect Effects 0.000 abstract description 4
- 150000004676 glycans Chemical class 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 102000004420 Creatine Kinase Human genes 0.000 description 17
- 108010042126 Creatine kinase Proteins 0.000 description 17
- 241000282472 Canis lupus familiaris Species 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 6
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 4
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241000234280 Liliaceae Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 230000003601 intercostal effect Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- -1 nitrous acid lipid Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101113430A CN101129400B (zh) | 2006-08-23 | 2006-08-23 | 玉竹多糖在制备治疗冠心病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101113430A CN101129400B (zh) | 2006-08-23 | 2006-08-23 | 玉竹多糖在制备治疗冠心病药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101129400A CN101129400A (zh) | 2008-02-27 |
CN101129400B true CN101129400B (zh) | 2010-12-08 |
Family
ID=39126910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101113430A Active CN101129400B (zh) | 2006-08-23 | 2006-08-23 | 玉竹多糖在制备治疗冠心病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101129400B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105194319A (zh) * | 2015-11-08 | 2015-12-30 | 长沙佰顺生物科技有限公司 | 一种玉竹多糖药物组合物的制备的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557842A (zh) * | 2004-02-02 | 2004-12-29 | 中南大学湘雅二医院 | 玉竹多糖的提取方法、药物制剂制备方法及其用途 |
-
2006
- 2006-08-23 CN CN2006101113430A patent/CN101129400B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557842A (zh) * | 2004-02-02 | 2004-12-29 | 中南大学湘雅二医院 | 玉竹多糖的提取方法、药物制剂制备方法及其用途 |
Non-Patent Citations (2)
Title |
---|
朱小平等.玉竹多糖.安徽大学学报(自然科学版) 1.1989,(1),全文. |
朱小平等.玉竹多糖.安徽大学学报(自然科学版) 1.1989,(1),全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN101129400A (zh) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101347422B (zh) | 丹酚酸a在预防和\或治疗糖尿病及并发症中的应用 | |
CN101230003A (zh) | 一种丹参丹酚酸a的制备方法 | |
CN102526340A (zh) | 一种防治高血压病的药物 | |
CN102861124B (zh) | 一种木香组合药物及其应用 | |
CN101129400B (zh) | 玉竹多糖在制备治疗冠心病药物中的应用 | |
CN101284042B (zh) | 一种减轻药物心脏毒性的甘草提取物及应用 | |
CN100471500C (zh) | 葛花苷的药物组合物及其应用 | |
CN101152196A (zh) | 三七总皂苷及其单体在制备治疗抑郁症药物中的应用 | |
CN100478002C (zh) | 治疗冠心病的复方缬草药物及其制备工艺 | |
CN103083429A (zh) | 降血脂中药组方 | |
CN103495115B (zh) | 一种对糖尿病具有治疗作用的药酒 | |
CN106620253B (zh) | 一种治疗缓慢性心律失常的中药组合物 | |
CN101461882B (zh) | 一种瓜蒌皮和薤白的提取物及其制备方法 | |
CN101444523B (zh) | 葛花苷在制备治疗骨质疏松症的药物组合物中的应用 | |
CN101095715A (zh) | 一种治疗心脑血管疾病的药物组合物 | |
CN103083423A (zh) | 一种治疗高血糖的中药方剂及其制备方法 | |
CN100496539C (zh) | 一种治疗冠心病的药物及其制备方法 | |
CN103800482B (zh) | 一种治疗心肌缺血的药物组合物及其制备方法和应用 | |
CN103505488A (zh) | 一种三七和沙棘中药组合物及制备方法 | |
CN114931600B (zh) | 一种预防和治疗高原反应的中药组合物及其制备方法 | |
CN102204956A (zh) | 一种用于中风恢复期的中药组合物及其制备方法 | |
CN101810684B (zh) | 一种含有中药提取物的协同药用组合物 | |
CN101396457B (zh) | 一种治疗多脏器功能不全综合征胃肠衰竭的中药组合物 | |
CN1330311C (zh) | 3,4’,5-三羟基茋-3-β-D-葡萄糖甙在抗心肌缺血药物制备中的用途 | |
CN104940554A (zh) | 一种治疗心脏病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN SHIJIA WEIKANG TECHNOLOGY DEVELOPMENT CO., Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20150114 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100084 HAIDIAN, BEIJING TO: 300000 BINHAI NEW DISTRICT, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150114 Address after: 300000 No. fourth, 5 Avenue, Tianjin Development Zone, Tianjin Patentee after: Tianjin Wei Kang Shijia Technology Development Co.,Ltd. Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 102206, Beijing, Changping District life road No. 6, No. 20, building 3 Patentee after: Tianjin Wei Kang Shijia Technology Development Co.,Ltd. Address before: 300000 No. fourth, 5 Avenue, Tianjin Development Zone Patentee before: Tianjin Wei Kang Shijia Technology Development Co.,Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Yawei Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Yawei Document name: Notice of termination of patent right |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Yawei Document name: Notice of supplement and correction for handling the formalities of restoration of rights |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Yawei Document name: Notice of supplement and correction for handling the formalities of restoration of rights |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Yawei Document name: Notice of Approval for Restoration of Rights Request |